Stougaard EB, Rossing P, Vistisen D, Banks P, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes. Diabetes Obes Metab 2023 Mar 5. doi: 10.1111/dom.15047.
PMID: 36872068